Morphine

What it is

Morphine is the main pain-relieving alkaloid of the opium poppy and the reference opioid against which others are measured. It acts as a full agonist at mu-opioid receptors, which sit throughout the brain, spinal cord and gut. It is given as immediate-release tablets or liquid, as 12-hour or 24-hour modified-release tablets and capsules, and by injection or infusion. It is a controlled substance, and the US label carries a boxed warning covering addiction, respiratory depression, accidental ingestion, combination with sedatives, and newborn withdrawal.

What the research says

Morphine reliably relieves moderate to severe cancer pain: across 62 trials pooled by Cochrane, 96% of individually reported participants reached no worse than mild pain, though Cochrane calls the evidence base poor and mostly old registration studies. For long-term non-cancer pain the picture is different. A 12-month randomised trial that started with immediate-release morphine found opioids were no better than non-opioid medicines for pain-related function, and worse for side effects. A meta-analysis of 96 trials found small average benefits, about a 12% chance of reaching a meaningful pain improvement, alongside more vomiting. For chronic breathlessness, a 284-person randomised trial found no benefit on the main outcome. Harms include respiratory depression, constipation, tolerance, physical dependence and addiction, and in registry data on acute coronary syndromes, higher mortality.

Evidence grade: Well established.

How it works

Drug class: Opioid analgesic; full mu-opioid receptor agonist (phenanthrene opiate)

Morphine switches on mu-opioid receptors, which are concentrated in the parts of the brain and spinal cord that carry and interpret pain signals. Turning them on dampens the pain message and changes how unpleasant the pain feels. The same receptors in the brainstem reduce the drive to breathe, which is why overdose kills by stopping breathing, and the same receptors in the gut slow it down, which is why constipation is near-universal. Because morphine is a full agonist there is no ceiling to its effect: higher doses keep producing more effect, including more respiratory depression. (Source 1)

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF MS CONTIN Addiction, Abuse, and Misuse Because the use of MS CONTIN exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warning and Precautions (5.1) ]. Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of MS CONTIN, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of MS CONTIN are essential. Instruct patients to swallow MS CONTIN tablets whole; crushing, chewing, or dissolving MS CONTIN tablets can cause rapid release and absorption of a potentially fatal dose of morphine [see Warnings and Precautions (5.2) ]. Accidental Ingestion Accidental ingestion of even one dose of MS CONTIN, especially by children, can result in a fatal overdose of morphine [see Warnings and Precautions (5.2) ]. Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of MS CONTIN and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate [see Warnings and Precautions (5.3) , Drug Interactions (7) ]. Neonatal Opioid Withdrawal Syndrome (NOWS) Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery [see Warnings and Precautions (5.4) ]. Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) Healthcare providers are strongly encouraged to complete a REMS-compliant education program, and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription [see Warning and Precautions (5.5) ].

(Source 2)

What it is used for

• Cochrane's review of 62 trials and 4,241 participants found morphine an effective analgesic, with 96% of individually reported participants reaching no worse than mild pain, but it rates the trial literature itself as poor, old and mostly designed only to compare formulations. Evidence: established. (Source 3)
• The current US label restricts the modified-release form to severe persistent pain that cannot be managed otherwise, and states the risks of addiction, overdose and death can occur at any dose or duration. Evidence: limited. (Source 1)
• In the 240-patient SPACE trial, which began with immediate-release morphine, opioids were not superior to non-opioid medicines for pain-related function over 12 months, pain intensity was slightly better on non-opioids, and side effects were more common on opioids. Evidence: not-supported. (Source 4)
• A 284-participant double-blind trial of 20 mg daily sustained-release morphine found no difference from placebo on breathlessness intensity or any secondary endpoint, though the morphine arm needed less rescue morphine. Evidence: not-supported. (Source 5)
• Widely used in practice but not an outcome-tested indication. In a 57,039-patient registry, morphine was associated with higher adjusted in-hospital mortality, and a randomised pharmacokinetic trial showed morphine blunts the antiplatelet effect of ticagrelor. Both are reasons for caution, not proof of harm. Evidence: disputed. (Source 6)

Interactions

• Benzodiazepines, other sedatives, gabapentinoids and other CNS depressants (label): Added together, these drugs suppress breathing and consciousness far more than either alone. This combination is in the boxed warning and can cause profound sedation, respiratory depression, coma and death. The label's own list of examples includes gabapentin and pregabalin, muscle relaxants, antipsychotics and other opioids. (Source 7)
• Alcohol (pharmacokinetic study): Two separate problems. The first is additive: alcohol plus morphine deepens sedation and breathing suppression, and this appears in the boxed warning. The second is formulation-specific: alcohol can break down some modified-release coatings so the dose arrives too fast. For one morphine product, 40% alcohol doubled the peak blood level and moved the peak from 9 hours to 4 hours. (Source 8)
• Ticagrelor and other oral P2Y12 antiplatelet drugs (pharmacokinetic study): Morphine slows the stomach, so an antiplatelet tablet taken at the same time is absorbed later and less completely. In a randomised double-blind trial in heart attack patients, 5 mg of intravenous morphine cut total ticagrelor exposure by 36% and left more patients with high platelet reactivity. (Source 9)
• Serotonergic medicines, including SSRIs, SNRIs, tricyclics, triptans, trazodone, mirtazapine and tramadol (label): Combining opioids with drugs that raise serotonin has caused serotonin syndrome, a reaction with agitation, fever, rigidity and autonomic instability. (Source 7)
• Sedating supplements such as valerian, kava, melatonin or cannabidiol (theoretical): The label's interaction warning is written around pharmacological class rather than product type: anything that adds central nervous system depression adds to morphine's effect on breathing and alertness. The named examples are prescription medicines and alcohol, not supplements; no supplement-specific pharmacokinetic study of morphine was found in the sources read here, so for sedating supplements this is extrapolation from class, not measured evidence. (Source 7)

Stopping it

• Physical dependence can appear after days to weeks of continued use, and stopping abruptly or cutting the dose sharply brings on withdrawal. The label describes the typical symptoms: restlessness, watering eyes, runny nose, yawning, sweating, chills, muscle aches and dilated pupils. (Source 10)
• There is no single correct taper. The US label suggests reducing by no more than 10% to 25% of the total daily dose at a time, every two to four weeks, for people who are physically dependent, with more rapid tapers possible after shorter courses. (Source 10)
• Rapid reduction or abrupt discontinuation in someone who is physically dependent is itself a documented danger, linked to serious withdrawal, uncontrolled pain and suicide. (Source 10)
• Observational data complicate the picture further: in 113,618 US patients on stable higher doses, tapering periods carried higher rates of overdose and of mental health crisis than non-tapered periods. The authors stress that this is an observational finding, not proof that tapering causes the harm. (Source 11)
• Tolerance is distinct from dependence and from addiction: it means the same dose does less over time, so a higher dose is needed for the same effect. (Source 10)

What goes wrong

Medication-related side effects were significantly more common on opioids than on non-opioids in the same 12-month trial. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 240 randomised.
• Who: As above.
• How long: 12 months.
• Result: Mean medication-related symptoms at 12 months 1.8 opioid vs 0.9 non-opioid (difference 0.9, 95% CI 0.3 to 1.5; overall P = .03) on a 0 to 19 checklist.
• Funding: not stated in the abstract.

Adverse medication-related symptoms were significantly more common in the opioid group over 12 months (overall P = .03)

The morphine arm of the breathlessness trial had more constipation and nausea or vomiting, with no respiratory depression recorded over seven days. (Source 5)

• Randomized trial, Moderate certainty.
• Size: 284 participants.
• Who: Adults with chronic breathlessness.
• How long: 7 days.
• Result: More constipation and nausea/vomiting in the morphine arm; no cases of respiratory depression or obtundation.
• Funding: not stated in the abstract.

The morphine group had more constipation and nausea/vomiting. There were no cases of respiratory depression nor obtundation.

Vomiting was about two and a half times as common on opioids as on placebo in trials that had already excluded people who could not tolerate a run-in. (Source 12)

• Meta-analysis, Moderate certainty.
• Size: Subset of the 96 RCTs that used a run-in period.
• Who: Adults with chronic non-cancer pain.
• How long: Varied by trial.
• Result: Vomiting 5.9% with opioids vs 2.3% with placebo.
• Funding: not stated in the abstract.

increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period)

About 6% of participants in the cancer pain trials stopped morphine because the adverse effects were intolerable. (Source 3)

• Systematic review, Low certainty.
• Size: 62 studies, 4,241 participants.
• Who: Adults and children with cancer pain.
• How long: Mostly short trials.
• Result: Approximately 6% discontinued because of intolerable adverse events; adverse events described as common and predictable.
• Funding: largely registration trials.

Adverse events were common, predictable, and approximately 6% of participants discontinued treatment with morphine because of intolerable adverse events.

Among people treated with opioids for chronic pain, pooled estimates put misuse at roughly a fifth to a quarter and addiction at about one in ten. (Source 13)

• Systematic review, Low certainty.
• Size: 38 studies.
• Who: People receiving opioids for chronic pain.
• How long: Varied; mostly cross-sectional prevalence assessments.
• Result: Misuse averaged 21% to 29% (95% CI range 13% to 38%); addiction averaged 8% to 12% (95% CI range 3% to 17%); individual study rates ranged from under 1% to 81%.
• Funding: not stated in the abstract.

Across most calculations, rates of misuse averaged between 21% and 29% (range, 95% confidence interval [CI]: 13%-38%). Rates of addiction averaged between 8% and 12% (range, 95% CI: 3%-17%).

In a large US registry of non-ST-elevation acute coronary syndromes, intravenous morphine was associated with higher adjusted in-hospital mortality. (Source 6)

• Cohort study, Very low certainty.
• Size: 57,039 patients at 443 US hospitals; 17,003 (29.8%) received morphine.
• Who: Patients presenting with non-ST-segment elevation acute coronary syndromes, January 2001 to June 2003.
• How long: In-hospital outcomes.
• Result: Adjusted odds of death 1.48 (95% CI 1.33 to 1.64) versus no morphine; 1.50 (95% CI 1.26 to 1.78) versus nitroglycerin; 1.41 (95% CI 1.26 to 1.57) on propensity matching.
• Funding: not stated in the abstract (CRUSADE quality improvement initiative)

Limit of this finding: This is a registry study, not a randomised trial: patients were not assigned to morphine, and sicker patients are more likely to be given it. The authors adjusted for measured differences and matched on propensity score, but that cannot rule out the possibility that the people given morphine were already at higher risk. The source itself reports an association with higher mortality and does not claim that morphine caused the extra deaths, and nor should a reader.

Patients treated with any morphine had a higher adjusted risk of death (odds ratio [OR] 1.48, 95% CI 1.33-1.64) than patients not treated with morphine.

Tapering long-term higher-dose opioids was associated with more overdose and mental health crisis events than continuing the stable dose. (Source 11)

• Cohort study, Low certainty.
• Size: 113,618 patients across 203,920 stable baseline periods.
• Who: US adults on stable opioid doses averaging at least 50 morphine milligram equivalents a day for 12 months, 2008 to 2019.
• How long: Up to 12 months of follow-up after a 7-month tapering window.
• Result: Overdose 9.3 vs 5.5 events per 100 person-years (adjusted rate difference 3.8, 95% CI 3.0 to 4.6; aIRR 1.68, 95% CI 1.53 to 1.85); mental health crisis 7.6 vs 3.3 per 100 person-years (aIRR 2.28, 95% CI 1.96 to 2.65)
• Funding: not stated in the abstract.

Posttapering patient periods were associated with an adjusted incidence rate of 9.3 overdose events per 100 person-years compared with 5.5 events per 100 person-years in nontapered periods

The US label records that tolerance and physical dependence develop with continued opioid use, and that abrupt stopping or a large dose cut produces withdrawal. (Source 10)

• Official position, Moderate certainty.
• Size: Not quantified.
• Who: People taking modified-release morphine.
• How long: Physical dependence may take days to weeks of continued use to become clinically significant.
• Result: Withdrawal signs include restlessness, lacrimation, rhinorrhoea, yawning, sweating, chills, myalgia and mydriasis; rapid tapering is linked to serious withdrawal, uncontrolled pain and suicide.
• Funding: regulatory position.

Physical dependence is a state that develops as a result of a physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

The boxed warning records fatal respiratory depression as a risk at initiation or after any dose increase, and death from combining opioids with benzodiazepines, other CNS depressants or alcohol. (Source 2)

• Official position, High certainty.
• Size: Not quantified.
• Who: Anyone prescribed or exposed to modified-release morphine, including children who swallow it accidentally.
• How long: Any dosage, any duration.
• Result: Risks listed as addiction, abuse and misuse leading to overdose and death; fatal respiratory depression; fatal overdose from a single accidental dose in a child; profound sedation, respiratory depression, coma and death with sedatives or alcohol; neonatal opioid withdrawal syndrome.
• Funding: regulatory position; boxed warning updated 12/2025.

Serious, life-threatening, or fatal respiratory depression may occur with use of MS CONTIN, especially during initiation or following a dosage increase.

What the evidence supports

Across the randomised literature on oral morphine for cancer pain, the great majority of individually reported participants reached no worse than mild pain. (Source 3)

• Systematic review, Low certainty.
• Size: 62 studies, 4,241 participants; individual results reported in 17 studies (377 and 638 participants for the two outcomes)
• Who: Adults and children with cancer pain.
• How long: Mostly short; 36 studies were cross-over designs of one to 15 days per arm.
• Result: No worse than mild pain in 96% (362/377); treatment success in 63% (400/638). Daily doses 25 mg to 2000 mg, average 100 to 250 mg.
• Funding: largely trials carried out for registration purposes, per the review.

'no worse than mild pain' was achieved by 96% of participants (362/377), and an outcome equivalent to treatment success in 63% (400/638)

What the evidence does not support

Over 12 months, opioid therapy starting with immediate-release morphine was no better than non-opioid medicines for pain-related function in chronic back or joint pain. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 240 randomised, 234 (97.5%) completed.
• Who: US veterans with moderate to severe chronic back pain or hip or knee osteoarthritis pain despite analgesics; mean age 58.3, 13.0% women.
• How long: 12 months.
• Result: 12-month BPI interference 3.4 opioid vs 3.3 non-opioid (difference 0.1, 95% CI -0.5 to 0.7; overall P = .58). Pain intensity favoured non-opioids (4.0 vs 3.5; difference 0.5, 95% CI 0.0 to 1.0)
• Funding: not stated in the abstract; conducted in Veterans Affairs primary care.

Groups did not significantly differ on pain-related function over 12 months (overall P = .58); mean 12-month BPI interference was 3.4 for the opioid group and 3.3 for the nonopioid group (difference, 0.1 [95% CI, -0.5 to 0.7]).

Regular low-dose sustained-release morphine did not reduce chronic breathlessness compared with placebo. (Source 5)

• Randomized trial, Moderate certainty.
• Size: 284 participants (145 morphine, 139 placebo) across 14 Australian services.
• Who: Adults with chronic breathlessness, modified MRC grade 2 or above, in cardiorespiratory and palliative care services.
• How long: 7 days.
• Result: Mean difference in breathlessness now -0.15 mm on a 0 to 100 mm scale (95% CI -4.59 to 4.29; p=0.95); no difference on any secondary endpoint. Placebo group used more rescue morphine (8.7 vs 5.8 doses; p=0.001)
• Funding: not stated in the abstract.

There was no difference between arms for the primary endpoint (mean difference -0.15 mm (95% CI -4.59 to 4.29; p=0.95)), nor secondary endpoints.

Where the evidence is mixed

Cochrane judged the morphine trial literature itself to be poor quality and at high risk of bias. (Source 3)

• Systematic review, Low certainty.
• Size: 62 studies, 4,241 participants.
• Who: Adults and children with cancer pain.
• How long: Mostly one to 15 days per arm.
• Result: Insufficient comparable data for meta-analysis or numbers needed to treat; most trials recruited fewer than 100 participants.
• Funding: largely registration trials.

The quality of the evidence is generally poor. Studies are old, often small, and were largely carried out for registration purposes

Across 96 randomised trials in chronic non-cancer pain, opioids produced small average benefits, with roughly one person in eight reaching a meaningful pain improvement. (Source 12)

• Meta-analysis, Moderate certainty.
• Size: 96 RCTs, 26,169 participants (61% female; median age 58)
• Who: Adults with chronic neuropathic, nociceptive, central-sensitisation or mixed non-cancer pain.
• How long: Varied by trial.
• Result: Pain WMD -0.69 cm on a 10 cm scale (95% CI -0.82 to -0.56); modelled risk difference for reaching the minimally important difference 11.9% (95% CI 9.7% to 14.1%); physical functioning WMD 2.04 points on SF-36 PCS.
• Funding: not stated in the abstract.

opioid use was associated with reduced pain (weighted mean difference [WMD], -0.69 cm [95% CI, -0.82 to -0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%])

Where the research disagrees

Whether opioids including morphine should be used for long-term non-cancer pain

• Krebs and colleagues, SPACE randomised trial (2018), Pragmatic 12-month randomised trial, 240 patients, masked outcome assessment: "Results do not support initiation of opioid therapy for moderate to severe chronic back pain or hip or knee osteoarthritis pain." (Source 4)
• Busse and colleagues, meta-analysis of 96 RCTs (2018), Systematic review and meta-analysis, 96 RCTs, 26,169 participants, GRADE-rated: "evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning" (Source 12)

Whether alcohol disrupts modified-release morphine and causes a dangerous rapid release

• Johnson and colleagues, pharmacokinetic study of morphine with sequestered naltrexone (2012), Open-label, single-dose, four-way crossover pharmacokinetic study in 32 healthy adults: "Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2-fold increase in C(max) and reduction of t(max) from 9 to 4 hours versus MS-sNT taken with water." (Source 8)
• Investigators of the KADIAN extended-release morphine alcohol study (2008), writing in the Perspective commentary of their abstract, Authors' interpretation of an open-label, randomised three-way crossover pharmacokinetic study in 32 healthy men; the trial's own result was that the 90% confidence intervals for AUC and peak concentration fell within 80%-125%: "results of this in vivo study indicate that the risk of alcohol-induced dose-dumping in connection with the use of KADIAN is negligible" (Source 14)

How much

• Reference intake: There is no reference intake for an opioid. Dosing is set by the prescriber and individualised. The US label for modified-release morphine (MS CONTIN, DailyMed, 2026) states that a single dose above 60 mg, or a total daily dose above 120 mg, is only for people already tolerant to a comparable opioid, and that the product is not for as-needed use. (Source 7)
• Upper limit: There is no stated maximum dose, because morphine is a full agonist with no ceiling to its effect. The US label (2026) instead instructs using the lowest effective dosage for the shortest duration, and defines opioid tolerance as at least 60 mg of morphine a day for a week or longer before higher single doses are used. (Source 7)
• Studied: Cochrane's cancer pain review found daily doses in trials ranging from 25 mg to 2000 mg, with averages between 100 mg and 250 mg. (Source 3)
• Studied: Currow and colleagues (2020) gave 20 mg daily oral sustained-release morphine plus a laxative, or placebo, for 7 days in chronic breathlessness. (Source 5)
• Studied: The SPACE trial's opioid step 1 was immediate-release morphine, oxycodone or hydrocodone/acetaminophen, titrated to effect over 12 months. (Source 4)
• Studied: The IMPRESSION trial used a single 5 mg intravenous dose of morphine before a ticagrelor loading dose. (Source 9)

A common belief, and what the research shows

The belief: Morphine is the strongest painkiller, so it must be the most effective choice for severe long-term pain.

What the research shows: Strength of receptor action is not the same as benefit over 12 months. In the SPACE randomised trial, where the opioid arm started with immediate-release morphine, "Treatment with opioids was not superior to treatment with nonopioid medications for improving pain-related function over 12 months." Side effects went the other way: "Adverse medication-related symptoms were significantly more common in the opioid group over 12 months (overall P = .03)". The picture is different in cancer pain, where Cochrane found most participants reached no worse than mild pain, and different again in chronic breathlessness, where a 284-person trial found "There was no difference between arms for the primary endpoint (mean difference -0.15 mm (95% CI -4.59 to 4.29; p=0.95)), nor secondary endpoints."

Questions and answers

What is it?

Morphine is a prescription opioid painkiller, originally extracted from the opium poppy, and the drug all other opioid strengths are measured against. It comes as immediate-release tablets and liquid, 12-hour and 24-hour modified-release tablets and capsules, and injections. It is a controlled substance and its US label carries a boxed warning. (Source 1)

What does it do in the body?

Morphine switches on mu-opioid receptors in the brain and spinal cord, which dulls the pain signal and changes how distressing the pain feels. The same receptors in the brainstem reduce the drive to breathe and the same receptors in the gut slow it down, which is why respiratory depression and constipation are its signature effects. Because it is a full agonist there is no ceiling: more drug keeps producing more effect, including more danger. (Source 1)

Is it good or bad for you?

Both, and the setting decides which. For cancer pain, Cochrane found most participants in the trial literature reached no worse than mild pain. For chronic back and joint pain, a 12-month randomised trial found it no better than non-opioid medicines and with more side effects, and for chronic breathlessness a 284-person trial found no benefit at all. Against those benefits sit addiction in roughly 8% to 12% of people treated long-term, fatal respiratory depression, and death when combined with sedatives or alcohol. (Source 4)

How do you get more of it?

Morphine is prescription-only and a controlled substance everywhere. Doses in the trials varied enormously: Cochrane's cancer pain review found daily doses from 25 mg to 2000 mg, averaging 100 to 250 mg, while the breathlessness trial used just 20 mg a day. The modified-release label restricts single doses above 60 mg, or daily doses above 120 mg, to people already tolerant to a comparable opioid. None of this is a recommendation for any reader. (Source 3)

If it is harmful, what reduces it?

In an overdose, the specific antidote is an opioid antagonist such as naloxone, which displaces morphine from the receptor; the label notes that giving an antagonist to someone physically dependent precipitates withdrawal. For coming off the drug deliberately, the approach is a gradual taper rather than removal: reducing by no more than 10% to 25% of the daily dose every two to four weeks in people who are physically dependent. Stopping suddenly is specifically warned against. (Source 10)

Why might someone be low in it or missing it?

The body does not make morphine, so nobody is deficient in it. Reasons someone in pain may not be receiving it include a judgement that non-opioid options are preferable, the restrictions in the current label, tolerance meaning the dose no longer works, and intolerable side effects: about 6% of participants in the cancer pain trials stopped because adverse effects were intolerable. (Source 3)

Which whole foods contain it or feed it?

No whole food contains pharmaceutical morphine. Poppy seeds come from the same plant and can carry traces of opiates sufficient to produce a positive urine drug screen, but they are not a source of a therapeutic dose. What matters about food and drink with morphine is alcohol, which both adds to the sedation and, with some modified-release products, can release the dose too quickly: 40% alcohol doubled the peak level of one product. (Source 8)

What happens if you do not have it?

In severe cancer pain, not having an opioid available means pain that other medicines often cannot reach: Cochrane's review found morphine brought most reported participants to no worse than mild pain. In chronic back and joint pain, the randomised evidence suggests not much is lost, since non-opioid medicines performed just as well on pain-related function over a year. For someone already physically dependent, suddenly having none produces withdrawal, which the label links to uncontrolled pain and suicide. (Source 3)

How can you test for it?

Morphine shows up on urine opiate immunoassays and can be measured precisely in blood or urine by mass spectrometry, which is how forensic and toxicology laboratories confirm it. Routine blood level monitoring is not used to guide pain treatment: dose is titrated to effect and side effects instead, because there is no ceiling effect and no target concentration. Immunoassay screens are prone to false positives, including from poppy seeds, so a positive screen is normally confirmed by a second method. No validated test tells you whether morphine is working other than the person's own reported pain and function, which is what the trials measured. (Source 1)

References

1. DailyMed, U.S. National Library of Medicine (Rhodes Pharmaceuticals LLC). MS CONTIN (morphine sulfate) extended-release tablets: indications, mechanism, interactions, dependence and tapering. 2026. Read the source
2. DailyMed, U.S. National Library of Medicine (Rhodes Pharmaceuticals LLC). MS CONTIN (morphine sulfate) extended-release tablets: BOXED WARNING. 2026. Read the source
3. Cochrane Database of Systematic Reviews (abstract read via Europe PMC REST). Oral morphine for cancer pain. 2016. PMID 27105021, DOI 10.1002/14651858.CD003868.pub4. Read the source
4. JAMA (abstract read via Europe PMC REST). Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. 2018. PMID 29509867, DOI 10.1001/jama.2018.0899. Read the source
5. Thorax (abstract read via Europe PMC REST). Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial. 2020. PMID 31558624, DOI 10.1136/thoraxjnl-2019-213681. Read the source
6. American Heart Journal (abstract read via Europe PMC REST). Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. 2005. PMID 15976786, DOI 10.1016/j.ahj.2005.02.010. Read the source
7. DailyMed, U.S. National Library of Medicine (Rhodes Pharmaceuticals LLC). MS CONTIN (morphine sulfate) extended-release tablets: Drug Interactions and opioid-tolerance dosing. 2026. Read the source
8. Journal of Clinical Pharmacology (abstract read via Europe PMC REST). Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. 2012. PMID 21593282, DOI 10.1177/0091270011403740. Read the source
9. European Heart Journal (abstract read via Europe PMC REST). Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. 2016. PMID 26491112, DOI 10.1093/eurheartj/ehv547. Read the source
10. DailyMed, U.S. National Library of Medicine (Rhodes Pharmaceuticals LLC). MS CONTIN (morphine sulfate) extended-release tablets: Drug Abuse and Dependence, and tapering. 2026. Read the source
11. JAMA (abstract read via Europe PMC REST). Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids. 2021. PMID 34342618, DOI 10.1001/jama.2021.11013. Read the source
12. JAMA (abstract read via Europe PMC REST). Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. 2018. PMID 30561481, DOI 10.1001/jama.2018.18472. Read the source
13. Pain (abstract read via Europe PMC REST). Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. 2015. PMID 25785523, DOI 10.1097/01.j.pain.0000460357.01998.f1. Read the source
14. The Journal of Pain (abstract read via Europe PMC REST). Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules - abstract, Perspective commentary. 2008. PMID 18201934, DOI 10.1016/j.jpain.2007.11.009. Read the source